Evidence map›Paper›PMID 33403501›Full record

ArticleInvestigational new drugs2021

NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.

Renata Scopim-Ribeiro, João Agostinho Machado-Neto, Christopher A Eide, Juan Luiz Coelho-Silva, Bruna Alves Fenerich, Jaqueline Cristina Fernandes, Priscila Santos Scheucher, Samantha L Savage Stevens, Paula de Melo Campos, Sara T Olalla Saad and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Renata Scopim-RibeiroDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
João Agostinho Machado-NetoDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Christopher A EideKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Juan Luiz Coelho-SilvaDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Bruna Alves FenerichDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Jaqueline Cristina FernandesDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Priscila Santos ScheucherDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Samantha L Savage StevensKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Paula de Melo CamposHematology and Transfusion Medicine Center, University of Campinas/Hemocentro UNICAMP, Campinas, São Paulo, Brazil.
Sara T Olalla SaadHematology and Transfusion Medicine Center, University of Campinas/Hemocentro UNICAMP, Campinas, São Paulo, Brazil.
Leonardo de Carvalho PalmaDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Lorena Lobo de Figueiredo-PontesDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Belinda Pinto SimõesDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Eduardo Magalhães RegoDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil.
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Fabiola TrainaDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirante 3900, Ribeirão Preto, São Paulo, Brazil. ftraina@fmrp.usp.br.
Universidade de São Paulo · BROregon Health & Science University · USHoward Hughes Medical Institute · USUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is successfully treated with BCR-ABL1 tyrosine kinase inhibitors, but a significant percentage of patients develop resistance. Insulin receptor substrate 1 (IRS1) has been shown to constitutively associate with BCR-ABL1, and IRS1-specific silencing leads to antineoplastic effects in CML cell lines. Here, we characterized the efficacy of NT157, a pharmacological inhibitor of IGF1R-IRS1/2, in CML cells and observed significantly reduced cell viability and proliferation, accompanied by induction of apoptosis. In human K562 cells and in murine Ba/F3 cells, engineered to express either wild-type BCR-ABL1 or the imatinib-resistant BCR-ABL1

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalDrug Resistance, NeoplasmFusion Proteins, bcr-ablGene Expression Regulation, NeoplasticHumansImatinib MesylateInsulin Receptor Substrate ProteinsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiceProtein Kinase InhibitorsAntineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylateInsulin Receptor Substrate ProteinsNT157 compoundProtein Kinase InhibitorsPyrogallolReceptor, IGF Type 1SulfonamidesBCR-ABL1Insulin receptor substrate 1LeukemogenesisNT157

Identifiers

PMID33403501
OpenAlexW3120498580

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.